MX2017007059A - Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación. - Google Patents

Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación.

Info

Publication number
MX2017007059A
MX2017007059A MX2017007059A MX2017007059A MX2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A
Authority
MX
Mexico
Prior art keywords
polypeptides
amino acid
acid sequence
modified
sequence lacking
Prior art date
Application number
MX2017007059A
Other languages
English (en)
Inventor
Krishnan Rajaraman
J Carr Francis
d jones Timothy
Fisher Richard
G E Holgate Robert
Asp Eva
Proschitsky Ming
Original Assignee
Proclara Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proclara Biosciences Inc filed Critical Proclara Biosciences Inc
Publication of MX2017007059A publication Critical patent/MX2017007059A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a polipéptidos que comprenden una porción de la proteína del gen bacteriófago filamentoso 3 (g3p) suficiente para unir a y/o desagregar amiloide, esto es, la porción N1-N2 de g3p y mutantes y fragmentos de esto, en donde esa secuencia de aminoácidos del g3p ha sido modificada a través de deleción, inserción o sustitución de aminoácidos para retirar una señal de glicosilación putativa. La invención además se refiere a tales polipéptidos que son también modificados a través de sustitución adicional de aminoácidos para ser sustancialmente menos inmunogénicos que la correspondiente secuencia de aminoácidos de tipo silvestre de g3p cuando se utiliza in vivo. Los polipéptidos de la invención mantienen su capacidad de unir y/o desagregar amiloide. La invención además se relaciona con el uso de estos polipéptidos de g3p modificados en el tratamiento y/o prevención de enfermedades asociadas con el plegamiento erróneo o la desagregación amiloide.
MX2017007059A 2014-12-03 2015-12-02 Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación. MX2017007059A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087052P 2014-12-03 2014-12-03
PCT/US2015/063476 WO2016090022A1 (en) 2014-12-03 2015-12-02 Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Publications (1)

Publication Number Publication Date
MX2017007059A true MX2017007059A (es) 2018-05-02

Family

ID=55273507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007059A MX2017007059A (es) 2014-12-03 2015-12-02 Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación.

Country Status (20)

Country Link
US (2) US10722551B2 (es)
EP (1) EP3227313B1 (es)
JP (2) JP6730988B2 (es)
KR (1) KR20170085132A (es)
CN (1) CN107250154A (es)
AR (1) AR102890A1 (es)
AU (1) AU2015358504A1 (es)
BR (1) BR112017011530A2 (es)
CA (1) CA2969128A1 (es)
DK (1) DK3227313T3 (es)
EA (1) EA201791212A1 (es)
ES (1) ES2910017T3 (es)
IL (1) IL252426A0 (es)
MX (1) MX2017007059A (es)
PH (1) PH12017501004A1 (es)
PL (1) PL3227313T3 (es)
PT (1) PT3227313T (es)
SG (1) SG11201704427YA (es)
TW (1) TW201632542A (es)
WO (1) WO2016090022A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093414A (zh) 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
EA030389B1 (ru) 2013-05-28 2018-07-31 Проклара Байосайенсиз, Инк. ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ИЗМЕНЕННУЮ АМИНОКИСЛОТНУЮ ПОСЛЕДОВАТЕЛЬНОСТЬ g3p БАКТЕРИОФАГА С ПОНИЖЕННОЙ ИММУНОГЕННОСТЬЮ
EP3227313B1 (en) 2014-12-03 2022-02-09 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
AU2019287623A1 (en) 2018-06-15 2021-01-07 Amyl Therapeutics Srl General amyloid interaction motif (GAIM)
WO2024119183A1 (en) 2022-12-02 2024-06-06 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3693671B2 (ja) 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2131003A1 (en) 1992-05-26 1993-12-09 Raymond G. Goodwin Novel cytokine that binds cd30
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
CN1202128C (zh) 1998-12-08 2005-05-18 拜奥威神有限公司 修饰蛋白的免疫原性
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
MXPA03007323A (es) 2001-02-19 2003-12-12 Merck Patent Gmbh Proteinas artificiales con inmunogenicidad reducida.
ATE339446T1 (de) 2001-03-08 2006-10-15 Merck Patent Gmbh Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität
DE10238846A1 (de) 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
PT1853285E (pt) 2005-02-01 2011-06-06 Univ Ramot Método para tratamento de inflamação associada a depósitos de amilóide e inflamação cerebral envolvendo microglia activada
CA2642473A1 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
US20090304726A1 (en) 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
US20090105090A1 (en) 2006-04-06 2009-04-23 Fumiaki Uchiyama Phage Display By Novel Filamentous Bacteriophage
CN101553567A (zh) 2006-07-21 2009-10-07 台拉维夫大学拉莫特 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法
SG10201502661SA (en) 2006-10-11 2015-05-28 Antitope Ltd T cell epitope databases
US20110182948A1 (en) 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque
MX2011005430A (es) 2008-11-24 2011-10-28 Univ Ramot Metodo para el tratamiento de la enfermedad de parkinson usando bacetriofago filamentoso.
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
KR20140051840A (ko) 2011-03-11 2014-05-02 라모트 앳 텔-아비브 유니버시티 리미티드 신경변성 타우오패씨를 치료하는 방법
CN104093414A (zh) 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
DK2906235T3 (en) * 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
EA030389B1 (ru) * 2013-05-28 2018-07-31 Проклара Байосайенсиз, Инк. ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ИЗМЕНЕННУЮ АМИНОКИСЛОТНУЮ ПОСЛЕДОВАТЕЛЬНОСТЬ g3p БАКТЕРИОФАГА С ПОНИЖЕННОЙ ИММУНОГЕННОСТЬЮ
EP3227313B1 (en) 2014-12-03 2022-02-09 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal

Also Published As

Publication number Publication date
EA201791212A1 (ru) 2018-01-31
TW201632542A (zh) 2016-09-16
PL3227313T3 (pl) 2022-05-09
EP3227313B1 (en) 2022-02-09
KR20170085132A (ko) 2017-07-21
EP3227313A1 (en) 2017-10-11
AU2015358504A8 (en) 2017-07-13
SG11201704427YA (en) 2017-06-29
US11723951B2 (en) 2023-08-15
BR112017011530A2 (pt) 2018-03-13
US20180207231A1 (en) 2018-07-26
WO2016090022A8 (en) 2017-06-22
US10722551B2 (en) 2020-07-28
PH12017501004A1 (en) 2017-12-18
WO2016090022A1 (en) 2016-06-09
AR102890A1 (es) 2017-03-29
CA2969128A1 (en) 2016-06-09
JP2020073610A (ja) 2020-05-14
CN107250154A (zh) 2017-10-13
JP2017538407A (ja) 2017-12-28
JP6730988B2 (ja) 2020-07-29
AU2015358504A1 (en) 2017-06-29
US20210015895A1 (en) 2021-01-21
WO2016090022A9 (en) 2016-08-25
ES2910017T3 (es) 2022-05-11
PT3227313T (pt) 2022-04-12
DK3227313T3 (da) 2022-04-19
IL252426A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
PH12017501004A1 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
PH12015502585A1 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
PH12019500596A1 (en) Recombinant binding proteins and their use
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
PH12017501792A1 (en) Recombinant binding proteins and their use
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
EP4275705A3 (en) Pancreatitis treatment
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
NZ733762A (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
MX2016014187A (es) Adenovirus que comprende una fraccion de union a albumina.
MX2017000378A (es) ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS.
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
WO2014204816A3 (en) Method for assessing protein identity and stability
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
WO2018053029A8 (en) Methods for treating pulmonary disease using inter-alpha inhibitor proteins
WO2017041001A3 (en) Insulin immunoglobulin fusion proteins
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
TW201612190A (en) Flavivirus virus like particle
MX2019005874A (es) Administracion intratecal de virus recombinante adeno-asociado que codifica la proteina 2 que une metilo-cpg.
IN2014CN00510A (es)
WO2015168488A3 (en) Islet amyloid polypeptides with improved solubility
WO2019036725A3 (en) PEPTIDE INHIBITORS OF TAU AGGREGATION
MX2018002616A (es) Proteina de fusion.